Strs Ohio Reduces Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Strs Ohio reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 69.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,400 shares of the specialty pharmaceutical company’s stock after selling 14,600 shares during the quarter. Strs Ohio’s holdings in Collegium Pharmaceutical were worth $196,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in COLL. Pacer Advisors Inc. grew its holdings in Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Collegium Pharmaceutical by 178.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after buying an additional 272,565 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in Collegium Pharmaceutical by 713.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after buying an additional 111,394 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in Collegium Pharmaceutical by 32.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after buying an additional 67,439 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Collegium Pharmaceutical by 1,019.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,670 shares of the specialty pharmaceutical company’s stock valued at $931,000 after buying an additional 37,946 shares in the last quarter.

Collegium Pharmaceutical Price Performance

COLL opened at $36.93 on Wednesday. The stock’s 50-day moving average price is $37.32 and its 200 day moving average price is $31.58. Collegium Pharmaceutical, Inc. has a 12-month low of $20.83 and a 12-month high of $40.95. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of 31.30 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

COLL has been the subject of several analyst reports. Jefferies Financial Group restated a “hold” rating and issued a $37.00 target price (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Piper Sandler reiterated an “overweight” rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Needham & Company LLC reiterated a “buy” rating and set a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. StockNews.com upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 23rd. Finally, Truist Financial increased their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $39.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.